

CASE REPORT

Rapidly and successful improvement of nail psoriasis with risankizumab

Diego Orsini¹  | Alessia Pacifico¹ | Paolo Iacovelli¹ | Pasquale Frascione² | Paola De Simone² | Chiara Assorgi³ | Flavia Pigliacelli¹

¹Clinical Dermatology Unit, IFO-San Gallicano Dermatological Institute-IRCCS, Rome, Italy

²Oncologic and Preventive Dermatology Unit, IFO-San Gallicano Dermatological Institute-IRCCS, Rome, Italy

³Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Napoli, Italy

Correspondence

Diego Orsini, Clinical Dermatology Unit, IFO-San Gallicano Dermatological Institute-IRCCS, Rome 00144, Italy.
Email: diegorsini@gmail.com

Key Clinical Message

This clinical case demonstrates quick resolution of nail psoriasis in a patient treated with risankizumab, highlighting the role of IL-23 in the pathogenesis of nail psoriasis.

KEYWORDS

nail, nail psoriasis, psoriasis, risankizumab

1 | INTRODUCTION

Psoriasis is a chronic inflammatory skin disease, characterized by erythematous and scaly plaques, with possible involvement of scalp, nails, and joints.¹ Nail involvement can affect up to 80% of patients with psoriasis, representing a risk factor for the development of psoriatic arthritis (PsA).²

2 | CASE PRESENTATION

We describe the case of a 47-year-old female patient with a 8-month history of plaque-type psoriasis with a concomitant nail involvement. At dermatological evaluation, erythematous and scaly patches and plaques were observed on trunk, extremities, and scalp with a PASI

score of 36. Moreover, also a nail dystrophy of both hands was observed, with subungual hyperkeratosis, pitting, onycholysis, and discoloration (Nail psoriasis severity index—NAPSI: 55) (Figure 1). Psoriasis had a strong impact of patient's quality of life, affecting her personal and working activities (Dermatology life quality index—DLQI: 20). Patient referred previous treatments with phototherapy (nb UVB) and cyclosporine, both suspended for inefficacy. A biologic treatment was started, with risankizumab 150 mg subcutaneously at Week 0, at Week 4 and then every 12 weeks. At Week 4, a strong clinical improvement was noted, with reduction of cutaneous lesions (PASI 14, DLQI: 4), and mild improvement of nail dystrophy (NAPSI 20). At Week 16, a complete resolution of cutaneous manifestations (PASI 0; DLQI 0) and of nail disease (NAPSI 0) was observed (Figure 1B).

All authors contributed equally to this work.

This is an open access article under the terms of the [Creative Commons Attribution-NonCommercial-NoDerivs](https://creativecommons.org/licenses/by-nc-nd/4.0/) License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.

© 2023 The Authors. *Clinical Case Reports* published by John Wiley & Sons Ltd.




FIGURE 1 (A) Nail psoriasis in both hands. (B): Week 16 Improvement of Nail Psoriasis (NAPSI: 0).

3 | CONCLUSION

Nail psoriasis is frequently associated with severe disease and can be accompanied by pain and functional impairment, with a strong impact on patients' quality of life.³ It is challenging to treat and is often resistant to common topical and systemic treatments. Risankizumab, a humanized immunoglobulin G1 monoclonal antibody that specifically inhibits interleukin (IL)-23 binding to p19 subunit, is recommended in patients with moderate-to-severe psoriasis. Some studies in the literature showed the efficacy and safety of risankizumab also on nail psoriasis.^{4,5}

We described this case to demonstrate quick resolution of nail psoriasis in a patient treated with risankizumab, highlighting the role of IL-23 in the pathogenesis of nail psoriasis.

AUTHOR CONTRIBUTIONS

Diego Orsini: Conceptualization; validation; writing – original draft; writing – review and editing. **Alessia Pacifico:** Supervision; visualization; writing – review and editing. **Paolo Iacovelli:** Supervision; validation; visualization. **Pasquale Frascione:** Supervision; validation; visualization. **Paola De Simone:** Supervision; validation; visualization. **Chiara Assorgi:** Validation; visualization; writing – original draft; writing – review and editing. **Flavia Pigliacelli:** Conceptualization; writing – original draft; writing – review and editing.

ACKNOWLEDGMENT

Open access funding provided by BIBLIOSAN.

CONFLICT OF INTEREST STATEMENT

None.

DATA AVAILABILITY STATEMENT

Additional data supporting the findings of this manuscript are available upon reasonable request to the corresponding author.

CONSENT

Written informed consent was obtained from the patient to publish this report in accordance with the journal's patient consent policy.

ORCID

Orsini Diego  <https://orcid.org/0000-0002-3190-3988>

REFERENCES

1. Nair PA, Badri T. Psoriasis. 2022. *StatPearls [Internet]*. StatPearls publishing; 2023.
2. Bardazzi F, Starace M, Bruni F, Magnano M, Piraccini BM, Alessandrini A. Nail psoriasis: an updated review and expert opinion on Available treatments. *Including Biologics Acta Derm Venereol*. 2019;99(6):516-523. doi:10.2340/00015555-3098
3. Thomas L, Azad J, Takwale A. Management of nail psoriasis. *Clin Exp Dermatol*. 2021;46(1):3-8. doi:10.1111/ced.14314
4. Kristensen LE, Soliman AM, Papp K, et al. Effects of risankizumab on nail psoriasis in patients with active psoriatic arthritis: results from KEEPSAKE 1. *J Eur Acad Dermatol Venereol*. 2022;36(5):e389-e392.
5. AlAjlan A, Qasim R, AlTassan F, et al. A case of nail psoriasis improved with treatment by risankizumab. *Oxf Med Case Reports*. 2022;2022:397-399.

How to cite this article: Orsini D, Pacifico A, Iacovelli P, et al. Rapidly and successful improvement of nail psoriasis with risankizumab. *Clin Case Rep*. 2023;11:e8035. doi:10.1002/ccr3.8035